BioCentury
ARTICLE | Clinical News

HE2000: Began Phase I/II trial

March 15, 1999 8:00 AM UTC

Hollis-Eden Pharmaceuticals Inc. (HEPH), San Diego, Calif. Product: HE2000 Business: Infectious diseases Therapeutic category: Immune stimulation, Viral replication Target: Host cell factors including...